Stability of trapped Bose-Einstein condensate under a density-dependent gauge field.

We study the ground-state stability of the trapped one-dimensional Bose-Einstein condensate under a density-dependent gauge field by variational and numerical methods. The competition of density-dependent gauge field and mean-field atomic interaction induces the instability of the ground state, which results in irregular dynamics. The threshold of the gauge field for exciting the instability is obtained analytically and confirmed numerically. When the gauge field is less than the threshold, the system is stable, and the gauge field induces chiral dynamics of the wave packet. When the gauge field is greater than the threshold, the system is unstable, and the ground-state wave packet will be deformed and fragmented. Interestingly, we find that as the gauge field approaches the threshold, strong dipolar and breathing dynamics take place, and strong modes mixing occurs, the instability of the system sets in. In addition, we show that the stability of the system can be well controlled by periodical modulation of the trapping potential. We provide theoretical evidence to understand and control the irregular dynamics associated with chiral superfluid induced by density-dependent gauge field.

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).

PURPOSE: There is no research evidence demonstrate which is the better partner strategy, endocrine therapy or chemotherapy, to combine with anti-HER2 therapy as the first-line management of hormone receptor (HR)-positive (HR+) and HER2-positive (HER2+) metastatic breast cancer (MBC). We wished to ascertain if trastuzumab plus endocrine therapy is noninferior to trastuzumab plus chemotherapy. PATIENTS AND METHODS: We conducted an open-label, noninferiority, phase III, randomized, controlled trial (NCT01950182) at nine hospitals in China. Participants, stratified by previous adjuvant endocrine therapy and disease status (recurrent disease vs. de novo metastasis), were assigned randomly (1:1) to receive trastuzumab plus endocrine therapy (per investigator's choice of oestrogen-receptor modulators or aromatase inhibitor, with/without concurrent ovarian suppression) or chemotherapy (per investigator's choice of taxanes, capecitabine, or vinorelbine). The primary endpoint was progression-free survival (PFS) with a noninferiority upper margin of 1.35 for the HR. The intention-to-treat population was used in primary and safety analyses. RESULTS: A total of 392 patients were enrolled and assigned randomly to receive trastuzumab plus endocrine therapy (ET group, n = 196) or trastuzumab plus chemotherapy (CT group, n = 196). After a median follow-up of 30.2 months [interquartile range (IQR) 15.0-44.7], the median PFS was 19.2 months [95% confidence interval (CI), 16.7-21.7)] in the ET group and 14.8 months (12.8-16.8) in the CT group (hazard ratio, 0.88; 95% CI, 0.71-1.09; Pnoninferiority < 0.0001). A significantly higher prevalence of toxicity was observed in the CT group compared with the ET group. CONCLUSIONS: Trastuzumab plus endocrine therapy was noninferior to trastuzumab plus chemotherapy in patients with HR+HER2+ MBC.